8 assets in Epstein-Barr Virus-Associated Lymphoproliferative Disorder

Therapeutic assets addressing Epstein-Barr Virus-Associated Lymphoproliferative Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tabelecleucel Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Pierre Fabre Medicament	P3	BB (66)
Ebv-Specific T Cells: B Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Ciusss de L'Est de l'Île de Montréal	P2	CCC (52)
Donor-Derived Ex-Vivo Expanded Ebv Tscm Ctl Epstein-Barr Virus-Associated Lymphoproliferative Disorder	University Hospital, Basel, Switzerland	P1/2	CCC (48)
Ebv-Ast Cell Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Daihong Liu	P1/2	CCC (48)
gp350 car-t Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Zhimin Zhai	P1/2	CCC (48)
Autologous Monocyte-Derived Dendritic Cells Pulsed With Ebv-Associated Antigen Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Kousai Bio Co., Ltd.	Early P1	NR ()
qs-21 Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Ohio State University Comprehensive Cancer Center	P1	NR ()